HER2 is the driver gene of breast cancer, and patients with HER2-positive breast cancer have shorter survival and poorer prognosis, while the BIG1-98 study showed that the prognosis of patients with triple-positive breast cancer remained poor even after 5-10 years of endocrine therapy (18). The gene discussed is ERBB2; the disease is breast carcinoma.